Present in up to 50 % of diabetic patients, diabetic peripheral neuropathy (DPN), is one of the most threatening complications of diabetes mellitus (D), constituting the leading cause of non-traumatic amputations. To date, a viable treatment for human DPN is not available. Although the pathophysiology of DPN is still quite poorly understood, increased oxidative stress and alterations in cyclooxygenase (COX) pathway activity, with subsequent perturbations in prostanoid metabolism, have been involved as critical factors. The overall hypothesis of this application is that in experimental D activation of the COX-2 pathway by oxidative stress, contributes to the biochemical, functional, neurotrophic and structural deficits of DPN. The objective of this proposal is to delineate the relationships between glucose-mediated oxidative stress, components of the COX pathway, and impaired neurotrophic support in the pathogenesis of DPN. Understanding these mechanisms and their relationship, may provide a rationale for the use of COX-2 selective inhibitors as a new and efficient therapeutic approach in patients with DPN. Streptozotocin-diabetic (STZ-D) rats, mice deficient in the expression of the COX-2 gene, and intervention with COX inhibition will be employed. Experimental DPN will be assessed with functional measurements of motor and sensory nerve conduction velocity (NCV) and nerve blood flow (NBF); light and electron microscopic nerve morphometry; biochemical parameters of nerve energy metabolism, oxidative stress, and antioxidative defense; measures of Schwann cell and sensory neuron apoptosis (AP).
The Specific Aims are:
Aim 1. To characterize the relationships of glucose-mediated oxidative stress to COX-2 pathway activation on the development of selected biochemical, functional, morphometric and neurotrophic defects in STZ-D rats.
Aim 2. Determine the time course for the development of selected biochemical, functional, morphometric, apoptotic and neurotrophic defects in STZ-D mice deficient in the human COX-2 gene. These studies will help to elucidate the mechanism by which oxidative stress and COX pathway influence the development of DPN and, facilitate the design of human studies, in which the aim will be the prevention or reversal of DPN.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21NS047653-01
Application #
6719238
Study Section
Metabolism Study Section (MET)
Program Officer
Mitler, Merrill
Project Start
2004-01-01
Project End
2005-12-31
Budget Start
2004-01-01
Budget End
2004-12-31
Support Year
1
Fiscal Year
2004
Total Cost
$169,969
Indirect Cost
Name
University of Toledo
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
807418939
City
Toledo
State
OH
Country
United States
Zip Code
43614
Erman, Audrey B; Kejner, Alexandra E; Hogikyan, Norman D et al. (2009) Disorders of cranial nerves IX and X. Semin Neurol 29:85-92
Pop-Busui, Rodica; Oral, Elif; Raffel, David et al. (2009) Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus. Metabolism 58:989-94
Kellogg, Aaron P; Converso, Kimber; Wiggin, Tim et al. (2009) Effects of cyclooxygenase-2 gene inactivation on cardiac autonomic and left ventricular function in experimental diabetes. Am J Physiol Heart Circ Physiol 296:H453-61
Kellogg, Aaron P; Cheng, Hsinlin Thomas; Pop-Busui, Rodica (2008) Cyclooxygenase-2 pathway as a potential therapeutic target in diabetic peripheral neuropathy. Curr Drug Targets 9:68-76
Kellogg, Aaron P; Wiggin, Tim D; Larkin, Dennis D et al. (2007) Protective effects of cyclooxygenase-2 gene inactivation against peripheral nerve dysfunction and intraepidermal nerve fiber loss in experimental diabetes. Diabetes 56:2997-3005
Kellogg, Aaron P; Pop-Busui, Rodica (2005) Peripheral nerve dysfunction in experimental diabetes is mediated by cyclooxygenase-2 and oxidative stress. Antioxid Redox Signal 7:1521-9